Neon Therapeutics (NTGN) Reaches New 1-Year Low at $5.51

Share on StockTwits

Neon Therapeutics Inc (NASDAQ:NTGN)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as $5.51 and last traded at $5.86, with a volume of 6649 shares traded. The stock had previously closed at $6.15.

A number of equities analysts have recently commented on the company. Zacks Investment Research raised Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Friday, November 16th. LADENBURG THALM/SH SH assumed coverage on Neon Therapeutics in a report on Monday, October 1st. They set a “buy” rating and a $20.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $18.08.

Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings results on Monday, November 12th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.12. Equities analysts anticipate that Neon Therapeutics Inc will post -5.17 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new position in shares of Neon Therapeutics during the 2nd quarter worth $105,000. Northern Trust Corp acquired a new position in Neon Therapeutics in the 2nd quarter worth about $137,000. Highland Capital Management LP acquired a new position in Neon Therapeutics in the 2nd quarter worth about $137,000. Bain Capital Public Equity Management LLC acquired a new position in Neon Therapeutics in the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp acquired a new position in Neon Therapeutics in the 3rd quarter worth about $141,000. 71.09% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4001382/neon-therapeutics-ntgn-reaches-new-1-year-low-at-5-51.html.

About Neon Therapeutics (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PIEDMONT LITHIU/S  Sets New 1-Year Low at $8.80
PIEDMONT LITHIU/S Sets New 1-Year Low at $8.80
Neon Therapeutics  Reaches New 1-Year Low at $5.51
Neon Therapeutics Reaches New 1-Year Low at $5.51
Brokerages Set Kforce Inc.  PT at $41.40
Brokerages Set Kforce Inc. PT at $41.40
Bed Bath & Beyond Inc.  Receives $15.86 Consensus Price Target from Brokerages
Bed Bath & Beyond Inc. Receives $15.86 Consensus Price Target from Brokerages
CRYPTO20 Price Down 25.5% This Week
CRYPTO20 Price Down 25.5% This Week
SpeedCash Price Tops $0.0162
SpeedCash Price Tops $0.0162


Leave a Reply

© 2006-2018 Ticker Report